Healthcare provider profile · identity verified

James Thomas Barker, M.D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · HICKORY, NC · NPI 1922189927

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show James Thomas Barker, M.D. received $508,882.98 in general payments during 2025 across 641 reported records.

E.R. Squibb & Sons, L.L.C. accounted for 22.6% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 25 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Caplyta, Ingrezza, Invega Sustenna, Lybalvi, Spravato, Trintellix.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viibryd by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Aristada by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lybalvi by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Invega Sustenna by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SPRAVATO as an associated drug or biological on 43813 records involving 17025 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Spravato by this doctor in 2024.

Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ingrezza by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trintellix by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$508,882.98

641 reported records · 20 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$115,218.85	22.6%	113	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$92,183.08	18.1%	93	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$89,667.74	17.6%	111	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$88,770.26	17.4%	119	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$58,736.91	11.5%	73	2025
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$41,153.51	8.1%	57	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$14,789.99	2.9%	25	2025
Eli Lilly and Company	Unresolved — no canonical attribution shown	$7,393.07	1.4%	4	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$210.92	0.0%	8	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$195.54	0.0%	8	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$143.84	0.0%	8	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$116.40	0.0%	5	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$59.87	0.0%	4	2025
Luye Pharma (USA) Ltd.	Unresolved — no canonical attribution shown	$51.61	0.0%	2	2025
Corium, LLC	Unresolved — no canonical attribution shown	$47.34	0.0%	3	2025
Noven Therapeutics, LLC	Unresolved — no canonical attribution shown	$37.51	0.0%	2	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$33.12	0.0%	2	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$32.69	0.0%	2	2025
Celgene Corporation	Unresolved — no canonical attribution shown	$21.13	0.0%	1	2025
Lilly USA, LLC	Unresolved — no canonical attribution shown	$19.60	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$341,930.00	112
Honoraria	$79,315.00	23
Consulting Fee	$40,690.25	9
Travel and Lodging	$34,397.38	171
Food and Beverage	$12,550.35	326

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
COBENFY Normalized: cobenfy	Drug	Celgene Corporation, E.R. Squibb & Sons, L.L.C.	$111,915.98	113	2025
Source payment records 2025-01-09 · E.R. Squibb & Sons, L.L.C. · $2,215.00 · Open Payments source 2025-01-14 · E.R. Squibb & Sons, L.L.C. · $21.66 · Open Payments source 2025-01-15 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-01-15 · E.R. Squibb & Sons, L.L.C. · $121.82 · Open Payments source 2025-01-15 · E.R. Squibb & Sons, L.L.C. · $209.23 · Open Payments source 2025-01-16 · E.R. Squibb & Sons, L.L.C. · $48.17 · Open Payments source 2025-01-16 · E.R. Squibb & Sons, L.L.C. · $4,430.00 · Open Payments source 2025-01-21 · E.R. Squibb & Sons, L.L.C. · $80.40 · Open Payments source 2025-01-21 · E.R. Squibb & Sons, L.L.C. · $38.88 · Open Payments source 2025-01-21 · E.R. Squibb & Sons, L.L.C. · $351.08 · Open Payments source 2025-01-21 · E.R. Squibb & Sons, L.L.C. · $47.60 · Open Payments source 2025-01-22 · E.R. Squibb & Sons, L.L.C. · $211.07 · Open Payments source 2025-01-22 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-01-27 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-01-27 · E.R. Squibb & Sons, L.L.C. · $226.00 · Open Payments source 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $82.41 · Open Payments source 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $151.53 · Open Payments source 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-02-04 · E.R. Squibb & Sons, L.L.C. · $4,984.00 · Open Payments source 2025-02-04 · E.R. Squibb & Sons, L.L.C. · $3,322.00 · Open Payments source 2025-02-05 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-02-14 · E.R. Squibb & Sons, L.L.C. · $830.50 · Open Payments source 2025-02-14 · E.R. Squibb & Sons, L.L.C. · $1,440.00 · Open Payments source 2025-02-14 · E.R. Squibb & Sons, L.L.C. · $4,430.00 · Open Payments source 2025-02-14 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-02-17 · E.R. Squibb & Sons, L.L.C. · $17.49 · Open Payments source 2025-02-20 · E.R. Squibb & Sons, L.L.C. · $4,763.00 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $206.50 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $52.83 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $267.40 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $208.60 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $260.40 · Open Payments source 2025-02-21 · E.R. Squibb & Sons, L.L.C. · $47.38 · Open Payments source 2025-02-27 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-02-27 · E.R. Squibb & Sons, L.L.C. · $62.27 · Open Payments source 2025-02-28 · E.R. Squibb & Sons, L.L.C. · $109.20 · Open Payments source 2025-02-28 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-03-11 · E.R. Squibb & Sons, L.L.C. · $22.55 · Open Payments source 2025-03-11 · E.R. Squibb & Sons, L.L.C. · $4.58 · Open Payments source 2025-03-18 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-03-18 · E.R. Squibb & Sons, L.L.C. · $3,322.00 · Open Payments source 2025-03-19 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-03-19 · E.R. Squibb & Sons, L.L.C. · $69.59 · Open Payments source 2025-03-19 · E.R. Squibb & Sons, L.L.C. · $451.87 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $30.00 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $292.60 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $128.80 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $23.95 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-03-20 · E.R. Squibb & Sons, L.L.C. · $4,430.00 · Open Payments source 2025-03-27 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-04-02 · E.R. Squibb & Sons, L.L.C. · $84.00 · Open Payments source 2025-04-03 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-04-10 · E.R. Squibb & Sons, L.L.C. · $45.35 · Open Payments source 2025-04-10 · E.R. Squibb & Sons, L.L.C. · $218.78 · Open Payments source 2025-04-10 · E.R. Squibb & Sons, L.L.C. · $95.36 · Open Payments source 2025-04-10 · E.R. Squibb & Sons, L.L.C. · $9.47 · Open Payments source 2025-04-14 · E.R. Squibb & Sons, L.L.C. · $20.45 · Open Payments source 2025-04-15 · E.R. Squibb & Sons, L.L.C. · $3,876.00 · Open Payments source 2025-04-18 · E.R. Squibb & Sons, L.L.C. · $243.60 · Open Payments source 2025-04-18 · E.R. Squibb & Sons, L.L.C. · $30.00 · Open Payments source 2025-04-25 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-04-25 · E.R. Squibb & Sons, L.L.C. · $3,655.00 · Open Payments source 2025-05-07 · E.R. Squibb & Sons, L.L.C. · $1,938.00 · Open Payments source 2025-05-08 · E.R. Squibb & Sons, L.L.C. · $105.10 · Open Payments source 2025-05-08 · E.R. Squibb & Sons, L.L.C. · $31.23 · Open Payments source 2025-05-08 · E.R. Squibb & Sons, L.L.C. · $311.35 · Open Payments source 2025-05-20 · E.R. Squibb & Sons, L.L.C. · $27.85 · Open Payments source 2025-05-20 · E.R. Squibb & Sons, L.L.C. · $4,763.00 · Open Payments source 2025-05-20 · E.R. Squibb & Sons, L.L.C. · $4,430.00 · Open Payments source 2025-05-21 · E.R. Squibb & Sons, L.L.C. · $125.00 · Open Payments source 2025-05-21 · E.R. Squibb & Sons, L.L.C. · $20.82 · Open Payments source 2025-05-21 · E.R. Squibb & Sons, L.L.C. · $242.41 · Open Payments source 2025-05-22 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-05-30 · E.R. Squibb & Sons, L.L.C. · $340.20 · Open Payments source 2025-05-30 · E.R. Squibb & Sons, L.L.C. · $31.39 · Open Payments source 2025-05-30 · E.R. Squibb & Sons, L.L.C. · $446.60 · Open Payments source 2025-05-30 · E.R. Squibb & Sons, L.L.C. · $25.99 · Open Payments source 2025-06-03 · E.R. Squibb & Sons, L.L.C. · $251.24 · Open Payments source 2025-06-03 · E.R. Squibb & Sons, L.L.C. · $104.57 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $3,876.00 · Open Payments source 2025-06-11 · E.R. Squibb & Sons, L.L.C. · $26.16 · Open Payments source 2025-06-16 · E.R. Squibb & Sons, L.L.C. · $16.20 · Open Payments source 2025-06-20 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-06-25 · E.R. Squibb & Sons, L.L.C. · $2,215.00 · Open Payments source 2025-06-25 · E.R. Squibb & Sons, L.L.C. · $4,984.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $18.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $147.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $30.00 · Open Payments source 2025-07-23 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-07-30 · E.R. Squibb & Sons, L.L.C. · $50.00 · Open Payments source 2025-07-30 · E.R. Squibb & Sons, L.L.C. · $95.20 · Open Payments source 2025-07-31 · Celgene Corporation · $21.13 · Open Payments source 2025-08-05 · E.R. Squibb & Sons, L.L.C. · $2,215.00 · Open Payments source 2025-08-19 · E.R. Squibb & Sons, L.L.C. · $53.20 · Open Payments source 2025-10-23 · E.R. Squibb & Sons, L.L.C. · $3,322.00 · Open Payments source 2025-11-07 · E.R. Squibb & Sons, L.L.C. · $4,430.00 · Open Payments source 2025-11-13 · E.R. Squibb & Sons, L.L.C. · $10.41 · Open Payments source 2025-11-13 · E.R. Squibb & Sons, L.L.C. · $108.85 · Open Payments source 2025-11-17 · E.R. Squibb & Sons, L.L.C. · $6.20 · Open Payments source 2025-11-17 · E.R. Squibb & Sons, L.L.C. · $20.08 · Open Payments source 2025-11-25 · E.R. Squibb & Sons, L.L.C. · $3,876.00 · Open Payments source 2025-11-26 · E.R. Squibb & Sons, L.L.C. · $2,215.00 · Open Payments source 2025-12-03 · E.R. Squibb & Sons, L.L.C. · $6.06 · Open Payments source 2025-12-03 · E.R. Squibb & Sons, L.L.C. · $2.13 · Open Payments source 2025-12-03 · E.R. Squibb & Sons, L.L.C. · $55.07 · Open Payments source 2025-12-04 · E.R. Squibb & Sons, L.L.C. · $140.00 · Open Payments source 2025-12-15 · E.R. Squibb & Sons, L.L.C. · $23.80 · Open Payments source 2025-12-23 · E.R. Squibb & Sons, L.L.C. · $18.95 · Open Payments source 2025-12-23 · E.R. Squibb & Sons, L.L.C. · $9.66 · Open Payments source 2025-12-30 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$92,138.24	92	2025
Source payment records 2025-01-07 · Neurocrine BioSciences, Inc. · $73.49 · Open Payments source 2025-01-23 · Neurocrine BioSciences, Inc. · $4,000.00 · Open Payments source 2025-01-23 · Neurocrine BioSciences, Inc. · $18.74 · Open Payments source 2025-02-10 · Neurocrine BioSciences, Inc. · $23.87 · Open Payments source 2025-02-13 · Neurocrine BioSciences, Inc. · $4,000.00 · Open Payments source 2025-02-13 · Neurocrine BioSciences, Inc. · $116.20 · Open Payments source 2025-02-13 · Neurocrine BioSciences, Inc. · $46.00 · Open Payments source 2025-02-13 · Neurocrine BioSciences, Inc. · $21.27 · Open Payments source 2025-02-14 · Neurocrine BioSciences, Inc. · $4,000.00 · Open Payments source 2025-02-14 · Neurocrine BioSciences, Inc. · $19.73 · Open Payments source 2025-02-28 · Neurocrine BioSciences, Inc. · $159.14 · Open Payments source 2025-02-28 · Neurocrine BioSciences, Inc. · $89.60 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $485.94 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $49.57 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $43.51 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $36.48 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $24.96 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $18.09 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $9.18 · Open Payments source 2025-03-01 · Neurocrine BioSciences, Inc. · $6.37 · Open Payments source 2025-03-02 · Neurocrine BioSciences, Inc. · $1,204.96 · Open Payments source 2025-03-02 · Neurocrine BioSciences, Inc. · $38.73 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $172.88 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $155.40 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $37.40 · Open Payments source 2025-03-06 · Neurocrine BioSciences, Inc. · $20.28 · Open Payments source 2025-03-10 · Neurocrine BioSciences, Inc. · $22.89 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $2,300.00 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $187.60 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $41.50 · Open Payments source 2025-03-12 · Neurocrine BioSciences, Inc. · $17.13 · Open Payments source 2025-03-25 · Neurocrine BioSciences, Inc. · $9,200.00 · Open Payments source 2025-03-28 · Neurocrine BioSciences, Inc. · $23.60 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $5,463.00 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $3,738.00 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $371.00 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $368.90 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $187.90 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $132.00 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $45.00 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $24.93 · Open Payments source 2025-03-31 · Neurocrine BioSciences, Inc. · $8.34 · Open Payments source 2025-04-11 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-04-11 · Neurocrine BioSciences, Inc. · $17.71 · Open Payments source 2025-04-15 · Neurocrine BioSciences, Inc. · $24.23 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $3,738.00 · Open Payments source 2025-05-15 · Neurocrine BioSciences, Inc. · $21.39 · Open Payments source 2025-05-28 · Neurocrine BioSciences, Inc. · $26.61 · Open Payments source 2025-05-31 · Neurocrine BioSciences, Inc. · $23.81 · Open Payments source 2025-06-19 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-06-23 · Neurocrine BioSciences, Inc. · $29.62 · Open Payments source 2025-06-24 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-06-24 · Neurocrine BioSciences, Inc. · $187.05 · Open Payments source 2025-06-24 · Neurocrine BioSciences, Inc. · $113.40 · Open Payments source 2025-06-24 · Neurocrine BioSciences, Inc. · $94.97 · Open Payments source 2025-06-24 · Neurocrine BioSciences, Inc. · $8.00 · Open Payments source 2025-06-26 · Neurocrine BioSciences, Inc. · $12.57 · Open Payments source 2025-07-15 · Neurocrine BioSciences, Inc. · $24.58 · Open Payments source 2025-08-11 · Neurocrine BioSciences, Inc. · $23.20 · Open Payments source 2025-08-18 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-08-18 · Neurocrine BioSciences, Inc. · $137.20 · Open Payments source 2025-08-18 · Neurocrine BioSciences, Inc. · $19.27 · Open Payments source 2025-08-25 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-08-25 · Neurocrine BioSciences, Inc. · $126.00 · Open Payments source 2025-08-26 · Neurocrine BioSciences, Inc. · $4,600.00 · Open Payments source 2025-08-26 · Neurocrine BioSciences, Inc. · $215.60 · Open Payments source 2025-08-26 · Neurocrine BioSciences, Inc. · $23.08 · Open Payments source 2025-08-26 · Neurocrine BioSciences, Inc. · $21.14 · Open Payments source 2025-09-15 · Neurocrine BioSciences, Inc. · $24.59 · Open Payments source 2025-09-18 · Neurocrine BioSciences, Inc. · $49.26 · Open Payments source 2025-10-14 · Neurocrine BioSciences, Inc. · $24.59 · Open Payments source 2025-11-02 · Neurocrine BioSciences, Inc. · $162.30 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $918.96 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $395.77 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $265.07 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $122.43 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $51.32 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $41.91 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $41.91 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $34.21 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $34.21 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $17.10 · Open Payments source 2025-11-03 · Neurocrine BioSciences, Inc. · $17.10 · Open Payments source 2025-11-07 · Neurocrine BioSciences, Inc. · $9.61 · Open Payments source 2025-11-20 · Neurocrine BioSciences, Inc. · $10.71 · Open Payments source 2025-11-26 · Neurocrine BioSciences, Inc. · $6,468.75 · Open Payments source 2025-11-26 · Neurocrine BioSciences, Inc. · $110.00 · Open Payments source 2025-12-11 · Neurocrine BioSciences, Inc. · $42.96 · Open Payments source 2025-12-18 · Neurocrine BioSciences, Inc. · $4.47 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$88,770.26	119	2025
Source payment records 2025-01-03 · Axsome Therapeutics, Inc. · $6.74 · Open Payments source 2025-01-09 · Axsome Therapeutics, Inc. · $11.14 · Open Payments source 2025-01-28 · Axsome Therapeutics, Inc. · $14.15 · Open Payments source 2025-02-04 · Axsome Therapeutics, Inc. · $5.73 · Open Payments source 2025-02-11 · Axsome Therapeutics, Inc. · $19.17 · Open Payments source 2025-02-27 · Axsome Therapeutics, Inc. · $24.32 · Open Payments source 2025-03-13 · Axsome Therapeutics, Inc. · $12.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $60.36 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $125.13 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $45.30 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $32.93 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $26.77 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $78.04 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $48.79 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $29.45 · Open Payments source 2025-03-15 · Axsome Therapeutics, Inc. · $234.83 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $288.40 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $4,725.00 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $3,038.00 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $41.85 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $117.72 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $288.40 · Open Payments source 2025-03-25 · Axsome Therapeutics, Inc. · $332.48 · Open Payments source 2025-03-27 · Axsome Therapeutics, Inc. · $27.01 · Open Payments source 2025-03-27 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-03-27 · Axsome Therapeutics, Inc. · $26.89 · Open Payments source 2025-03-27 · Axsome Therapeutics, Inc. · $358.40 · Open Payments source 2025-04-02 · Axsome Therapeutics, Inc. · $16.77 · Open Payments source 2025-04-03 · Axsome Therapeutics, Inc. · $8,775.00 · Open Payments source 2025-04-04 · Axsome Therapeutics, Inc. · $505.40 · Open Payments source 2025-04-08 · Axsome Therapeutics, Inc. · $3,038.00 · Open Payments source 2025-04-08 · Axsome Therapeutics, Inc. · $124.46 · Open Payments source 2025-04-09 · Axsome Therapeutics, Inc. · $5.80 · Open Payments source 2025-04-24 · Axsome Therapeutics, Inc. · $10.84 · Open Payments source 2025-05-12 · Axsome Therapeutics, Inc. · $19.66 · Open Payments source 2025-05-22 · Axsome Therapeutics, Inc. · $15.62 · Open Payments source 2025-06-05 · Axsome Therapeutics, Inc. · $10.35 · Open Payments source 2025-06-10 · Axsome Therapeutics, Inc. · $24.98 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $29.83 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $9.19 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $190.40 · Open Payments source 2025-06-25 · Axsome Therapeutics, Inc. · $187.60 · Open Payments source 2025-07-01 · Axsome Therapeutics, Inc. · $6.68 · Open Payments source 2025-07-01 · Axsome Therapeutics, Inc. · $1.35 · Open Payments source 2025-07-10 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-07-10 · Axsome Therapeutics, Inc. · $243.60 · Open Payments source 2025-07-16 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-07-16 · Axsome Therapeutics, Inc. · $357.70 · Open Payments source 2025-07-21 · Axsome Therapeutics, Inc. · $19.76 · Open Payments source 2025-07-22 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-07-22 · Axsome Therapeutics, Inc. · $26.60 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $19.30 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $4,725.00 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $3,038.00 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $6.43 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $58.55 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $200.90 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $213.50 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $14.70 · Open Payments source 2025-07-24 · Axsome Therapeutics, Inc. · $227.47 · Open Payments source 2025-08-14 · Axsome Therapeutics, Inc. · $16.78 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $3,038.00 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $4,725.00 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $60.31 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $23.98 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $119.12 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $11.90 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $212.80 · Open Payments source 2025-09-23 · Axsome Therapeutics, Inc. · $213.50 · Open Payments source 2025-09-30 · Axsome Therapeutics, Inc. · $1,350.00 · Open Payments source 2025-10-01 · Axsome Therapeutics, Inc. · $19.17 · Open Payments source 2025-10-16 · Axsome Therapeutics, Inc. · $24.81 · Open Payments source 2025-10-20 · Axsome Therapeutics, Inc. · $17.40 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $18.63 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $4,388.00 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $92.64 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $41.11 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $147.70 · Open Payments source 2025-10-21 · Axsome Therapeutics, Inc. · $175.00 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $58.17 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $150.50 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $267.63 · Open Payments source 2025-10-22 · Axsome Therapeutics, Inc. · $148.40 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $10.14 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $12.69 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $67.98 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $273.83 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $387.86 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $25.00 · Open Payments source 2025-10-28 · Axsome Therapeutics, Inc. · $135.80 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $26.45 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $40.21 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $93.80 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $16.80 · Open Payments source 2025-10-29 · Axsome Therapeutics, Inc. · $4.00 · Open Payments source 2025-10-30 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-10-30 · Axsome Therapeutics, Inc. · $240.10 · Open Payments source 2025-11-04 · Axsome Therapeutics, Inc. · $19.05 · Open Payments source 2025-11-05 · Axsome Therapeutics, Inc. · $3,375.00 · Open Payments source 2025-11-05 · Axsome Therapeutics, Inc. · $54.43 · Open Payments source 2025-11-05 · Axsome Therapeutics, Inc. · $705.00 · Open Payments source 2025-11-05 · Axsome Therapeutics, Inc. · $172.90 · Open Payments source 2025-11-06 · Axsome Therapeutics, Inc. · $2,025.00 · Open Payments source 2025-11-06 · Axsome Therapeutics, Inc. · $240.10 · Open Payments source 2025-11-12 · Axsome Therapeutics, Inc. · $14.18 · Open Payments source 2025-11-20 · Axsome Therapeutics, Inc. · $15.08 · Open Payments source 2025-12-04 · Axsome Therapeutics, Inc. · $15.14 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$58,986.10	76	2025
Source payment records 2025-01-06 · Alkermes, Inc. · $118.64 · Open Payments source 2025-01-20 · Alkermes, Inc. · $22.89 · Open Payments source 2025-01-28 · Alkermes, Inc. · $81.04 · Open Payments source 2025-01-29 · Alkermes, Inc. · $25.71 · Open Payments source 2025-02-11 · Alkermes, Inc. · $18.67 · Open Payments source 2025-02-11 · Alkermes, Inc. · $255.56 · Open Payments source 2025-02-11 · Alkermes, Inc. · $122.07 · Open Payments source 2025-02-12 · Alkermes, Inc. · $23.01 · Open Payments source 2025-02-18 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-02-18 · Alkermes, Inc. · $338.80 · Open Payments source 2025-02-21 · Alkermes, Inc. · $21.98 · Open Payments source 2025-02-27 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-02-27 · Alkermes, Inc. · $148.40 · Open Payments source 2025-02-27 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-02-27 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-02-27 · Alkermes, Inc. · $148.40 · Open Payments source 2025-03-17 · Alkermes, Inc. · $155.68 · Open Payments source 2025-03-17 · Alkermes, Inc. · $128.48 · Open Payments source 2025-03-27 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-04-02 · Alkermes, Inc. · $10.24 · Open Payments source 2025-04-16 · Alkermes, Inc. · $55.35 · Open Payments source 2025-04-16 · Alkermes, Inc. · $658.00 · Open Payments source 2025-04-29 · Alkermes, Inc. · $578.92 · Open Payments source 2025-04-29 · Alkermes, Inc. · $101.68 · Open Payments source 2025-05-01 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-05-01 · Alkermes, Inc. · $129.54 · Open Payments source 2025-05-07 · Alkermes, Inc. · $960.00 · Open Payments source 2025-05-13 · Alkermes, Inc. · $234.74 · Open Payments source 2025-05-16 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-05-16 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-05-20 · Alkermes, Inc. · $3,060.00 · Open Payments source 2025-05-22 · Alkermes, Inc. · $286.20 · Open Payments source 2025-05-22 · Alkermes, Inc. · $94.72 · Open Payments source 2025-05-28 · Alkermes, Inc. · $21.05 · Open Payments source 2025-05-29 · Alkermes, Inc. · $40.38 · Open Payments source 2025-05-29 · Alkermes, Inc. · $315.70 · Open Payments source 2025-06-04 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-06-18 · Alkermes, Inc. · $22.40 · Open Payments source 2025-06-26 · Alkermes, Inc. · $515.20 · Open Payments source 2025-07-01 · Alkermes, Inc. · $10.02 · Open Payments source 2025-07-02 · Alkermes, Inc. · $30.43 · Open Payments source 2025-07-02 · Alkermes, Inc. · $153.30 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-07-29 · Alkermes, Inc. · $258.77 · Open Payments source 2025-07-29 · Alkermes, Inc. · $96.16 · Open Payments source 2025-07-30 · Alkermes, Inc. · $17.76 · Open Payments source 2025-08-01 · Alkermes, Inc. · $27.51 · Open Payments source 2025-08-06 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-08-06 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-08-13 · Alkermes, Inc. · $192.50 · Open Payments source 2025-08-13 · Alkermes, Inc. · $40.99 · Open Payments source 2025-08-19 · Alkermes, Inc. · $288.35 · Open Payments source 2025-08-19 · Alkermes, Inc. · $123.06 · Open Payments source 2025-08-20 · Alkermes, Inc. · $246.10 · Open Payments source 2025-08-20 · Alkermes, Inc. · $31.91 · Open Payments source 2025-08-20 · Alkermes, Inc. · $48.00 · Open Payments source 2025-08-20 · Alkermes, Inc. · $184.10 · Open Payments source 2025-08-20 · Alkermes, Inc. · $113.64 · Open Payments source 2025-09-03 · Alkermes, Inc. · $2,100.00 · Open Payments source 2025-09-03 · Alkermes, Inc. · $33.81 · Open Payments source 2025-09-03 · Alkermes, Inc. · $51.10 · Open Payments source 2025-09-03 · Alkermes, Inc. · $2,100.00 · Open Payments source 2025-09-03 · Alkermes, Inc. · $332.50 · Open Payments source 2025-09-03 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-09-03 · Alkermes, Inc. · $58.14 · Open Payments source 2025-09-03 · Alkermes, Inc. · $282.80 · Open Payments source 2025-09-03 · Alkermes, Inc. · $18.00 · Open Payments source 2025-09-17 · Alkermes, Inc. · $27.00 · Open Payments source 2025-10-29 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-10-29 · Alkermes, Inc. · $248.02 · Open Payments source 2025-10-29 · Alkermes, Inc. · $32.99 · Open Payments source 2025-10-29 · Alkermes, Inc. · $252.00 · Open Payments source 2025-10-29 · Alkermes, Inc. · $32.00 · Open Payments source 2025-11-25 · Alkermes, Inc. · $19.55 · Open Payments source 2025-12-08 · Alkermes, Inc. · $17.49 · Open Payments source 2025-12-16 · Alkermes, Inc. · $24.65 · Open Payments source
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$41,153.51	57	2025
Source payment records 2025-01-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.11 · Open Payments source 2025-01-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $93.00 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.40 · Open Payments source 2025-02-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.87 · Open Payments source 2025-03-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.71 · Open Payments source 2025-03-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.17 · Open Payments source 2025-04-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.18 · Open Payments source 2025-05-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.91 · Open Payments source 2025-05-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.71 · Open Payments source 2025-05-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $12.22 · Open Payments source 2025-06-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,497.50 · Open Payments source 2025-06-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.31 · Open Payments source 2025-06-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.83 · Open Payments source 2025-07-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.33 · Open Payments source 2025-08-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.77 · Open Payments source 2025-08-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.96 · Open Payments source 2025-08-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.18 · Open Payments source 2025-09-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.81 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $48.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.06 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.54 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $23.63 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $238.26 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $105.53 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $19.79 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $85.40 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.78 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $54.64 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $143.19 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $114.73 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $207.92 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.53 · Open Payments source 2025-11-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.89 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.14 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.61 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.69 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.30 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.21 · Open Payments source 2025-12-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.13 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,220.00 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$36,913.50	49	2025
Source payment records 2025-01-03 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $143.68 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $142.99 · Open Payments source 2025-02-05 · Janssen Pharmaceuticals, Inc · $550.13 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $100.00 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-02-06 · Janssen Pharmaceuticals, Inc · $110.03 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $14.70 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $9.80 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $33.34 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $13.93 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $120.44 · Open Payments source 2025-02-07 · Janssen Pharmaceuticals, Inc · $50.00 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $35.79 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $56.57 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $13.69 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $14.60 · Open Payments source 2025-02-08 · Janssen Pharmaceuticals, Inc · $12.69 · Open Payments source 2025-02-19 · Janssen Pharmaceuticals, Inc · $156.10 · Open Payments source 2025-03-03 · Janssen Pharmaceuticals, Inc · $4,145.00 · Open Payments source 2025-03-03 · Janssen Pharmaceuticals, Inc · $485.80 · Open Payments source 2025-03-12 · Janssen Pharmaceuticals, Inc · $9,810.00 · Open Payments source 2025-03-13 · Janssen Pharmaceuticals, Inc · $19.79 · Open Payments source 2025-03-27 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-03-28 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-08 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-22 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-22 · Janssen Pharmaceuticals, Inc · $174.04 · Open Payments source 2025-04-22 · Janssen Pharmaceuticals, Inc · $125.00 · Open Payments source 2025-04-23 · Janssen Pharmaceuticals, Inc · $145.42 · Open Payments source 2025-04-23 · Janssen Pharmaceuticals, Inc · $97.04 · Open Payments source 2025-04-24 · Janssen Pharmaceuticals, Inc · $158.13 · Open Payments source 2025-04-28 · Janssen Pharmaceuticals, Inc · $2,073.00 · Open Payments source 2025-04-28 · Janssen Pharmaceuticals, Inc · $4.34 · Open Payments source 2025-04-28 · Janssen Pharmaceuticals, Inc · $4,145.00 · Open Payments source 2025-04-28 · Janssen Pharmaceuticals, Inc · $2,073.00 · Open Payments source 2025-04-28 · Janssen Pharmaceuticals, Inc · $4,145.00 · Open Payments source 2025-05-05 · Janssen Pharmaceuticals, Inc · $648.90 · Open Payments source 2025-05-05 · Janssen Pharmaceuticals, Inc · $70.00 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $23.75 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $732.90 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $65.00 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $33.00 · Open Payments source 2025-05-29 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-07-02 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-07-11 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-07-24 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source 2025-08-21 · Janssen Pharmaceuticals, Inc · $27.91 · Open Payments source 2025-08-28 · Janssen Pharmaceuticals, Inc · $1,220.00 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$31,066.66	48	2025
Source payment records 2025-01-06 · Alkermes, Inc. · $118.64 · Open Payments source 2025-01-20 · Alkermes, Inc. · $22.89 · Open Payments source 2025-02-12 · Alkermes, Inc. · $23.01 · Open Payments source 2025-02-21 · Alkermes, Inc. · $21.98 · Open Payments source 2025-03-27 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-04-02 · Alkermes, Inc. · $10.24 · Open Payments source 2025-04-15 · Alkermes, Inc. · $319.95 · Open Payments source 2025-04-15 · Alkermes, Inc. · $119.94 · Open Payments source 2025-04-16 · Alkermes, Inc. · $129.92 · Open Payments source 2025-04-30 · Alkermes, Inc. · $124.52 · Open Payments source 2025-05-01 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-05-01 · Alkermes, Inc. · $68.73 · Open Payments source 2025-05-01 · Alkermes, Inc. · $567.70 · Open Payments source 2025-05-01 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-05-16 · Alkermes, Inc. · $2,100.00 · Open Payments source 2025-05-16 · Alkermes, Inc. · $2,100.00 · Open Payments source 2025-05-28 · Alkermes, Inc. · $21.05 · Open Payments source 2025-05-29 · Alkermes, Inc. · $32.00 · Open Payments source 2025-05-29 · Alkermes, Inc. · $366.10 · Open Payments source 2025-06-06 · Alkermes, Inc. · $596.97 · Open Payments source 2025-06-06 · Alkermes, Inc. · $266.96 · Open Payments source 2025-06-06 · Alkermes, Inc. · $91.06 · Open Payments source 2025-06-06 · Alkermes, Inc. · $72.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $32.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $27.15 · Open Payments source 2025-06-06 · Alkermes, Inc. · $14.67 · Open Payments source 2025-06-06 · Alkermes, Inc. · $12.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $179.61 · Open Payments source 2025-06-06 · Alkermes, Inc. · $31.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $7.11 · Open Payments source 2025-06-17 · Alkermes, Inc. · $234.53 · Open Payments source 2025-06-17 · Alkermes, Inc. · $127.70 · Open Payments source 2025-07-01 · Alkermes, Inc. · $10.02 · Open Payments source 2025-07-02 · Alkermes, Inc. · $175.70 · Open Payments source 2025-07-02 · Alkermes, Inc. · $90.30 · Open Payments source 2025-07-02 · Alkermes, Inc. · $84.00 · Open Payments source 2025-07-02 · Alkermes, Inc. · $24.60 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-07-09 · Alkermes, Inc. · $6,500.00 · Open Payments source 2025-08-01 · Alkermes, Inc. · $27.51 · Open Payments source 2025-08-13 · Alkermes, Inc. · $40.99 · Open Payments source 2025-09-03 · Alkermes, Inc. · $134.40 · Open Payments source 2025-09-17 · Alkermes, Inc. · $27.00 · Open Payments source 2025-10-03 · Alkermes, Inc. · $2,290.00 · Open Payments source 2025-11-25 · Alkermes, Inc. · $19.55 · Open Payments source 2025-12-08 · Alkermes, Inc. · $17.49 · Open Payments source 2025-12-16 · Alkermes, Inc. · $24.65 · Open Payments source
ARISTADA INITIO Normalized: aristada initio	Drug	Alkermes, Inc.	$30,681.64	35	2025
Source payment records 2025-03-27 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-04-15 · Alkermes, Inc. · $319.95 · Open Payments source 2025-04-15 · Alkermes, Inc. · $119.94 · Open Payments source 2025-04-16 · Alkermes, Inc. · $129.92 · Open Payments source 2025-04-30 · Alkermes, Inc. · $124.52 · Open Payments source 2025-05-01 · Alkermes, Inc. · $3,820.00 · Open Payments source 2025-05-01 · Alkermes, Inc. · $68.73 · Open Payments source 2025-05-01 · Alkermes, Inc. · $567.70 · Open Payments source 2025-05-01 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-05-16 · Alkermes, Inc. · $2,100.00 · Open Payments source 2025-05-16 · Alkermes, Inc. · $2,100.00 · Open Payments source 2025-05-29 · Alkermes, Inc. · $32.00 · Open Payments source 2025-05-29 · Alkermes, Inc. · $366.10 · Open Payments source 2025-06-06 · Alkermes, Inc. · $596.97 · Open Payments source 2025-06-06 · Alkermes, Inc. · $266.96 · Open Payments source 2025-06-06 · Alkermes, Inc. · $91.06 · Open Payments source 2025-06-06 · Alkermes, Inc. · $72.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $32.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $27.15 · Open Payments source 2025-06-06 · Alkermes, Inc. · $14.67 · Open Payments source 2025-06-06 · Alkermes, Inc. · $12.14 · Open Payments source 2025-06-06 · Alkermes, Inc. · $179.61 · Open Payments source 2025-06-06 · Alkermes, Inc. · $31.37 · Open Payments source 2025-06-06 · Alkermes, Inc. · $7.11 · Open Payments source 2025-06-17 · Alkermes, Inc. · $234.53 · Open Payments source 2025-06-17 · Alkermes, Inc. · $127.70 · Open Payments source 2025-07-02 · Alkermes, Inc. · $175.70 · Open Payments source 2025-07-02 · Alkermes, Inc. · $90.30 · Open Payments source 2025-07-02 · Alkermes, Inc. · $84.00 · Open Payments source 2025-07-02 · Alkermes, Inc. · $24.60 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-07-09 · Alkermes, Inc. · $2,485.00 · Open Payments source 2025-07-09 · Alkermes, Inc. · $6,500.00 · Open Payments source 2025-09-03 · Alkermes, Inc. · $134.40 · Open Payments source 2025-10-03 · Alkermes, Inc. · $2,290.00 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$21,823.41	24	2025
Source payment records 2025-02-17 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-17 · Janssen Pharmaceuticals, Inc · $6.49 · Open Payments source 2025-04-17 · Janssen Pharmaceuticals, Inc · $15.08 · Open Payments source 2025-04-18 · Janssen Pharmaceuticals, Inc · $139.40 · Open Payments source 2025-04-25 · Janssen Pharmaceuticals, Inc · $3,330.00 · Open Payments source 2025-05-07 · Janssen Pharmaceuticals, Inc · $3,885.00 · Open Payments source 2025-05-07 · Janssen Pharmaceuticals, Inc · $1,943.00 · Open Payments source 2025-05-08 · Janssen Pharmaceuticals, Inc · $4.07 · Open Payments source 2025-05-08 · Janssen Pharmaceuticals, Inc · $137.20 · Open Payments source 2025-05-09 · Janssen Pharmaceuticals, Inc · $137.90 · Open Payments source 2025-05-14 · Janssen Pharmaceuticals, Inc · $78.68 · Open Payments source 2025-05-14 · Janssen Pharmaceuticals, Inc · $29.43 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $179.90 · Open Payments source 2025-05-22 · Janssen Pharmaceuticals, Inc · $3,885.00 · Open Payments source 2025-05-23 · Janssen Pharmaceuticals, Inc · $1,943.00 · Open Payments source 2025-05-27 · Janssen Pharmaceuticals, Inc · $240.80 · Open Payments source 2025-05-27 · Janssen Pharmaceuticals, Inc · $22.20 · Open Payments source 2025-07-10 · Janssen Pharmaceuticals, Inc · $555.00 · Open Payments source 2025-08-12 · Janssen Pharmaceuticals, Inc · $19.95 · Open Payments source 2025-08-28 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-09-25 · Janssen Pharmaceuticals, Inc · $310.31 · Open Payments source 2025-09-26 · Janssen Pharmaceuticals, Inc · $3,885.00 · Open Payments source 2025-09-26 · Janssen Pharmaceuticals, Inc · $150.00 · Open Payments source 2025-12-18 · Janssen Pharmaceuticals, Inc · $915.00 · Open Payments source
INVEGA TRINZA Normalized: invega trinza	Drug	Janssen Pharmaceuticals, Inc	$21,384.38	17	2025
Source payment records 2025-02-17 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-04-25 · Janssen Pharmaceuticals, Inc · $3,330.00 · Open Payments source 2025-05-07 · Janssen Pharmaceuticals, Inc · $3,885.00 · Open Payments source 2025-05-07 · Janssen Pharmaceuticals, Inc · $1,943.00 · Open Payments source 2025-05-08 · Janssen Pharmaceuticals, Inc · $4.07 · Open Payments source 2025-05-08 · Janssen Pharmaceuticals, Inc · $137.20 · Open Payments source 2025-05-09 · Janssen Pharmaceuticals, Inc · $137.90 · Open Payments source 2025-05-21 · Janssen Pharmaceuticals, Inc · $179.90 · Open Payments source 2025-05-22 · Janssen Pharmaceuticals, Inc · $3,885.00 · Open Payments source 2025-05-23 · Janssen Pharmaceuticals, Inc · $1,943.00 · Open Payments source 2025-05-27 · Janssen Pharmaceuticals, Inc · $240.80 · Open Payments source 2025-05-27 · Janssen Pharmaceuticals, Inc · $22.20 · Open Payments source 2025-07-10 · Janssen Pharmaceuticals, Inc · $555.00 · Open Payments source 2025-08-28 · Janssen Pharmaceuticals, Inc · $5.50 · Open Payments source 2025-09-25 · Janssen Pharmaceuticals, Inc · $310.31 · Open Payments source 2025-09-26 · Janssen Pharmaceuticals, Inc · $3,885.00 · Open Payments source 2025-12-18 · Janssen Pharmaceuticals, Inc · $915.00 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$14,823.11	27	2025
Source payment records 2025-02-05 · Otsuka America Pharmaceutical, Inc. · $26.69 · Open Payments source 2025-02-25 · Lundbeck LLC · $17.79 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $25.58 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $19.70 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $6.93 · Open Payments source 2025-04-18 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-06-02 · Otsuka America Pharmaceutical, Inc. · $24.61 · Open Payments source 2025-06-14 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source 2025-06-23 · Otsuka America Pharmaceutical, Inc. · $3,078.00 · Open Payments source 2025-06-25 · Otsuka America Pharmaceutical, Inc. · $877.50 · Open Payments source 2025-06-27 · Otsuka America Pharmaceutical, Inc. · $3,078.00 · Open Payments source 2025-07-02 · Lundbeck LLC · $15.33 · Open Payments source 2025-07-07 · Otsuka America Pharmaceutical, Inc. · $26.50 · Open Payments source 2025-07-08 · Otsuka America Pharmaceutical, Inc. · $40.81 · Open Payments source 2025-07-16 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-07-17 · Otsuka America Pharmaceutical, Inc. · $14.63 · Open Payments source 2025-07-25 · Otsuka America Pharmaceutical, Inc. · $9.24 · Open Payments source 2025-07-25 · Otsuka America Pharmaceutical, Inc. · $145.60 · Open Payments source 2025-08-06 · Otsuka America Pharmaceutical, Inc. · $31.71 · Open Payments source 2025-09-08 · Otsuka America Pharmaceutical, Inc. · $25.98 · Open Payments source 2025-09-19 · Otsuka America Pharmaceutical, Inc. · $14.60 · Open Payments source 2025-09-20 · Otsuka America Pharmaceutical, Inc. · $3,078.00 · Open Payments source 2025-10-02 · Otsuka America Pharmaceutical, Inc. · $20.79 · Open Payments source 2025-10-02 · Otsuka America Pharmaceutical, Inc. · $109.20 · Open Payments source 2025-10-06 · Otsuka America Pharmaceutical, Inc. · $21.40 · Open Payments source 2025-10-14 · Otsuka America Pharmaceutical, Inc. · $11.46 · Open Payments source 2025-12-01 · Otsuka America Pharmaceutical, Inc. · $26.06 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$210.92	8	2025
Source payment records 2025-01-08 · Vanda Pharmaceuticals Inc. · $26.78 · Open Payments source 2025-02-03 · Vanda Pharmaceuticals Inc. · $33.19 · Open Payments source 2025-03-03 · Vanda Pharmaceuticals Inc. · $31.09 · Open Payments source 2025-04-07 · Vanda Pharmaceuticals Inc. · $27.17 · Open Payments source 2025-05-07 · Vanda Pharmaceuticals Inc. · $30.09 · Open Payments source 2025-10-15 · Vanda Pharmaceuticals Inc. · $25.76 · Open Payments source 2025-11-10 · Vanda Pharmaceuticals Inc. · $28.25 · Open Payments source 2025-12-16 · Vanda Pharmaceuticals Inc. · $8.59 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$143.84	8	2025
Source payment records 2025-03-25 · Bausch Health US, LLC · $19.47 · Open Payments source 2025-04-21 · Bausch Health US, LLC · $20.03 · Open Payments source 2025-06-23 · Bausch Health US, LLC · $25.04 · Open Payments source 2025-09-16 · Bausch Health US, LLC · $23.65 · Open Payments source 2025-09-16 · Bausch Health US, LLC · $7.87 · Open Payments source 2025-10-28 · Bausch Health US, LLC · $25.37 · Open Payments source 2025-10-30 · Bausch Health US, LLC · $3.63 · Open Payments source 2025-12-18 · Bausch Health US, LLC · $18.78 · Open Payments source
WELLBUTRIN Normalized: wellbutrin	Drug	Bausch Health US, LLC	$143.84	8	2025
Source payment records 2025-03-25 · Bausch Health US, LLC · $19.47 · Open Payments source 2025-04-21 · Bausch Health US, LLC · $20.03 · Open Payments source 2025-06-23 · Bausch Health US, LLC · $25.04 · Open Payments source 2025-09-16 · Bausch Health US, LLC · $23.65 · Open Payments source 2025-09-16 · Bausch Health US, LLC · $7.87 · Open Payments source 2025-10-28 · Bausch Health US, LLC · $25.37 · Open Payments source 2025-10-30 · Bausch Health US, LLC · $3.63 · Open Payments source 2025-12-18 · Bausch Health US, LLC · $18.78 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$116.40	5	2025
Source payment records 2025-07-29 · Supernus Pharmaceuticals, Inc. · $23.01 · Open Payments source 2025-08-05 · Supernus Pharmaceuticals, Inc. · $23.16 · Open Payments source 2025-09-09 · Supernus Pharmaceuticals, Inc. · $24.19 · Open Payments source 2025-10-07 · Supernus Pharmaceuticals, Inc. · $23.03 · Open Payments source 2025-11-04 · Supernus Pharmaceuticals, Inc. · $23.01 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$98.17	3	2025
Source payment records 2025-03-05 · Teva Pharmaceuticals USA, Inc. · $58.19 · Open Payments source 2025-03-18 · Teva Pharmaceuticals USA, Inc. · $18.18 · Open Payments source 2025-09-29 · Teva Pharmaceuticals USA, Inc. · $21.80 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$97.37	5	2025
Source payment records 2025-01-06 · Teva Pharmaceuticals USA, Inc. · $15.11 · Open Payments source 2025-05-12 · Teva Pharmaceuticals USA, Inc. · $21.59 · Open Payments source 2025-06-20 · Teva Pharmaceuticals USA, Inc. · $23.57 · Open Payments source 2025-07-22 · Teva Pharmaceuticals USA, Inc. · $17.43 · Open Payments source 2025-08-27 · Teva Pharmaceuticals USA, Inc. · $19.67 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$59.87	4	2025
Source payment records 2025-05-29 · Takeda Pharmaceuticals U.S.A., Inc. · $14.47 · Open Payments source 2025-07-23 · Takeda Pharmaceuticals U.S.A., Inc. · $14.47 · Open Payments source 2025-10-13 · Takeda Pharmaceuticals U.S.A., Inc. · $15.43 · Open Payments source 2025-11-12 · Takeda Pharmaceuticals U.S.A., Inc. · $15.50 · Open Payments source
ERZOFRI EXTENDED-RELEASE Normalized: erzofri extended release	Drug	Luye Pharma (USA) Ltd.	$51.61	2	2025
Source payment records 2025-06-19 · Luye Pharma (USA) Ltd. · $24.02 · Open Payments source 2025-10-27 · Luye Pharma (USA) Ltd. · $27.59 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$47.34	3	2025
Source payment records 2025-07-03 · Corium, LLC · $21.16 · Open Payments source 2025-08-07 · Corium, LLC · $20.01 · Open Payments source 2025-12-18 · Corium, LLC · $6.17 · Open Payments source
Secuado Normalized: secuado	Drug	Noven Therapeutics, LLC	$37.51	2	2025
Source payment records 2025-02-18 · Noven Therapeutics, LLC · $16.21 · Open Payments source 2025-07-21 · Noven Therapeutics, LLC · $21.30 · Open Payments source
Xelstrym Normalized: xelstrym	Drug	Noven Therapeutics, LLC	$37.51	2	2025
Source payment records 2025-02-18 · Noven Therapeutics, LLC · $16.21 · Open Payments source 2025-07-21 · Noven Therapeutics, LLC · $21.30 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$32.69	2	2025
Source payment records 2025-03-04 · ABBVIE INC. · $15.91 · Open Payments source 2025-03-26 · ABBVIE INC. · $16.78 · Open Payments source
AMYVID Normalized: amyvid	Drug	Lilly USA, LLC	$19.60	1	2025
Source payment records 2025-09-30 · Lilly USA, LLC · $19.60 · Open Payments source
KISUNLA Normalized: kisunla	Drug	Lilly USA, LLC	$19.60	1	2025
Source payment records 2025-09-30 · Lilly USA, LLC · $19.60 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
ARISTADA aristada	2025	Aristada	2024	32 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	112	exact normalized	Medicare Part D
INGREZZA ingrezza	2025	Ingrezza	2024	46	exact normalized	Medicare Part D
INVEGA SUSTENNA invega sustenna	2025	Invega Sustenna	2024	20	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
SPRAVATO spravato	2025	Spravato	2024	240 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	54 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VIIBRYD open payments reported associated product	CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050	Viibryd · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	ARISTADA open payments reported associated product	CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566	Aristada · 2024 Exact normalized brand match · 1 Part D row	32	suppressed by CMS
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	112	13
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	112	13
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	INVEGA SUSTENNA open payments reported associated product	CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262	Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row	20	12
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	SPRAVATO open payments reported associated product	CMS Open Payments — General Payments 43813 supporting records · 17025 recipient NPIs · example record 1174223254	Spravato · 2024 Exact normalized brand match · 1 Part D row	240	suppressed by CMS
Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference	2025	INGREZZA open payments reported associated product	CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729	Ingrezza · 2024 Exact normalized brand match · 1 Part D row	46	11
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	54	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Spravato	Esketamine Hcl	240	suppressed
Bupropion Xl	Bupropion Hcl	195	55
Lamotrigine	Lamotrigine	176	49
Metformin Hcl Er	Metformin Hcl	134	30
Gabapentin	Gabapentin	125	34
Clonazepam	Clonazepam	123	28
Caplyta	Lumateperone Tosylate	112	13
Quetiapine Fumarate	Quetiapine Fumarate	106	31
Buspirone Hcl	Buspirone Hcl	78	23
Clozapine	Clozapine	63	suppressed
Olanzapine	Olanzapine	58	18
Lisinopril	Lisinopril	57	14
Trazodone Hcl	Trazodone Hcl	56	12
Zolpidem Tartrate	Zolpidem Tartrate	56	13
Trintellix	Vortioxetine Hydrobromide	54	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	53	13
Levothyroxine Sodium	Levothyroxine Sodium	51	18
Aripiprazole	Aripiprazole	49	19
Atorvastatin Calcium	Atorvastatin Calcium	49	18
Donepezil Hcl	Donepezil Hcl	48	13
Atenolol	Atenolol	46	19
Ingrezza	Valbenazine Tosylate	46	11
Sertraline Hcl	Sertraline Hcl	38	13
Pantoprazole Sodium	Pantoprazole Sodium	36	16
Memantine Hcl	Memantine Hcl	35	11
Tizanidine Hcl	Tizanidine Hcl	34	13
Aristada	Aripiprazole Lauroxil	32	suppressed
Metformin Hcl	Metformin Hcl	31	12
Vilazodone Hcl	Vilazodone Hcl	31	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	30	suppressed
Lorazepam	Lorazepam	30	suppressed
Carvedilol	Carvedilol	29	suppressed
Divalproex Sodium Er	Divalproex Sodium	27	suppressed
Risperidone	Risperidone	26	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	25	suppressed
Diazepam	Diazepam	23	suppressed
Lithium Carbonate Er	Lithium Carbonate	22	suppressed
Potassium Chloride	Potassium Chloride	22	suppressed
Invega Sustenna	Paliperidone Palmitate	20	12
Losartan Potassium	Losartan Potassium	20	suppressed
Omeprazole	Omeprazole	20	suppressed
Ozempic	Semaglutide	20	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	19	suppressed
Famotidine	Famotidine	19	suppressed
Furosemide	Furosemide	19	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Amlodipine Besylate	Amlodipine Besylate	15	suppressed
Divalproex Sodium	Divalproex Sodium	15	13
Lybalvi	Olanzapine/Samidorphan Malate	15	suppressed
Ondansetron Hcl	Ondansetron Hcl	15	suppressed
Naltrexone Hcl	Naltrexone Hcl	14	suppressed
Topiramate	Topiramate	14	suppressed
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	13	suppressed
Sucralfate	Sucralfate	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Cyproheptadine Hcl	Cyproheptadine Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Guanfacine Hcl	Guanfacine Hcl	12	suppressed
Methylphenidate Er	Methylphenidate Hcl	12	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	12	suppressed
Viibryd	Vilazodone Hcl	12	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Metoprolol Succinate	Metoprolol Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$508,882.98 · 641 records	E.R. Squibb & Sons, L.L.C.	AMYVID, APLENZIN, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, ERZOFRI EXTENDED-RELEASE, FANAPT, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, KISUNLA, LYBALVI, Qelbree, REXULTI, SPRAVATO, Secuado, TRINTELLIX, UZEDY, VRAYLAR, WELLBUTRIN, Xelstrym	9	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Aristada play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error